Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AC Immune SA (NASDAQ: ACIU) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. AC Immune files annual reports on Form 20-F and furnishes current reports on Form 6-K, which together offer insight into its clinical-stage biopharmaceutical operations focused on precision prevention of neurodegenerative diseases.
Through its 6-K submissions, AC Immune furnishes interim condensed consolidated financial statements prepared under IFRS, management’s discussion and analysis of financial condition and results of operations, and press releases covering clinical and corporate developments. Examples include reports on interim Phase 2 data for the anti-alpha-synuclein active immunotherapy ACI-7104.056 in Parkinson’s disease, strategic pipeline refocusing and workforce reductions, and quarterly cash position and loss figures.
Investors can use these filings to track how AC Immune funds and prioritizes its programs, including active immunotherapies such as ACI-24.060 and ACI-35.030, small-molecule candidates like the NLRP3 inhibitor ACI-19764, and diagnostic PET tracers such as ACI-19626 and ACI-15916. Governance-related filings, including annual general meeting results, board and committee elections, compensation approvals and auditor reappointments, are also furnished on Form 6-K and incorporated by reference into the company’s shelf registration statements.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR, and AI-powered tools can help summarize lengthy 20-F and 6-K materials, highlight key risk factors, and surface important changes in clinical, financial or governance disclosures. This allows users to quickly understand how AC Immune’s regulatory reporting reflects the evolution of its neurodegeneration-focused pipeline and collaboration agreements.
A planned insider sale of common stock has been disclosed under Rule 144. The person named in the notice, Andrea Pfeifer, plans to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on or around 01/15/2026, with an indicated aggregate market value of $110,100.00. The filing notes that 100,600,000 shares of this class are outstanding and lists NASDAQ as the securities exchange.
The shares to be sold were originally acquired on 06/01/2012 by exercising stock options issued by the company and paid for in cash. Over the past three months, there was a separate 10b5-1 sale for Andrea Pfeifer of 500 common shares on 10/29/2025 for gross proceeds of $2,000.00. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
AC Immune SA reported that it has positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial of ACI-7104.056, its wholly owned anti‑alpha‑synuclein active immunotherapy for early Parkinson’s disease. The trial is evaluating this candidate in patients with early-stage Parkinson’s.
The company disclosed that these results were first shared in a press release dated December 11, 2025, which is attached as an exhibit to this Form 6-K for more detailed information.
AC Immune SA (ACIU) submitted a Form 144 notifying the proposed sale of 45,000 common shares through Morgan Stanley Smith Barney LLC on or about 10/03/2025 with an aggregate market value of $140,850.00. The filer acquired these shares on 06/01/2012 by previously exercised stock options and paid cash for them. The filing lists recent sales by the same account under 10b5-1 plans totaling multiple transactions between 07/24/2025 and 09/29/2025, including sales of 29,400 and 5,600 shares on 09/25/2025 and 09/29/2025, respectively. The filer attests no undisclosed material adverse information and includes standard Rule 144 representations.
AC Immune SA reports the outcome of a strategic review, deciding to concentrate spending on its most important R&D assets. The focus will be on three clinical-stage active immunotherapy programs, including two in collaborations with pharmaceutical partners, and on small molecule programs targeting NLRP3 and Tau.
To support this sharper focus, AC Immune plans to reduce its workforce by around 30%. The company states that these actions are expected to extend its available cash for operations to the end of the third quarter of 2027, giving it more time to advance its key pipeline programs.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
